Diarrhoea Predominant Irritable Bowel Syndrome Completed Phase 2 Trials for Rifamycin (DB11753)

Also known as: Diarrhea-predominant Irritable Bowel Syndrome / IBS, Diarrhea Predominant / Irritable Bowel Syndrome With Diarrhea / Diarrhea Predominant Irritable Bowel Syndrome / Diarrhea- Predominant Irritable Bowel Syndrome / Diarrhea Dominant Irritable Bowel Syndrome / Irritable bowel syndrome with diarrhea (disorder) / Irritable bowel syndrome without diarrhea / Irritable colon / Colitis mucous / Mucous colitis / Colon spastic / Spastic colon / Irritable colon syndrome / Functional bowel syndrome / Irritable bowel / Irritable bowel syndrome / Irritable colon (disorder)

IndicationStatusPhase
DBCOND0075933 (Diarrhoea Predominant Irritable Bowel Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03099785Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-DTreatment